RT Book, Section A1 Leavitt, Andrew D. A1 Price, Erika Leemann A2 Papadakis, Maxine A. A2 McPhee, Stephen J. A2 Rabow, Michael W. A2 McQuaid, Kenneth R. SR Print(0) ID 1193159068 T1 Primary VTE Prevention & Treatment in Severe COVID-19 T2 Current Medical Diagnosis & Treatment 2023 YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264687343 LK accessmedicine.mhmedical.com/content.aspx?aid=1193159068 RD 2024/03/28 AB Key Clinical Updates in Primary VTE Prevention & Treatment in Severe COVID-19Therapeutic dosing of anticoagulation may benefit some patients who are hospitalized in the acute care setting with COVID-19, who have very elevated D-dimer values and require supplemental oxygen, and who have low bleeding risk.Patients who are critically ill in ICUs have not been shown to benefit from therapeutic dosing.There is no clear benefit from VTE prophylaxis for patients with COVID-19 who do not require hospitalization.ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR et al. N Engl J Med. [PMID: 34351721]REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC et al. N Engl J Med. [PMID: 34351722]Spyropoulos AC. JAMA Intern Med. [PMID: 34617959]